1.Non-resectable bilateral malignant granulosa cell tumor with metastasis in a dog: a case report
Young-Tak CHO ; Chang-Hyeon CHOI ; Keon KIM ; Chang-Yun JE ; Jae-Beom JOO ; Seung-Ju KANG ; Sang-Ik PARK ; Woong-Bin RO ; Chang-Min LEE
Korean Journal of Veterinary Research 2025;65(1):e7-
A seventeen-year-old Shih Tzu presented with severe abdominal distension and labored respiration. Radiographic examination revealed severe ascites and pleural effusion. Bilateral malignant ovarian tumor, which was non-resectable due to distant metastasis, was diagnosed through computed tomography and cytology. Chemotherapy with carboplatin significantly delayed fluid accumulation, improving quality of life for 6 months. Necropsy later confirmed metastatic malignant bilateral granulosa cell tumor involving lymph nodes, liver, and thoracic cavity. This case demonstrates the feasibility of chemotherapy and symptomatic management as alternatives to ovariohysterectomy in metastatic ovarian tumors, highlighting its potential to extend survival and maintain quality of life when surgery is contraindicated.
2.Evidence‑based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions
Sung‑Hoon JUNG ; Youngil KOH ; Min Kyoung KIM ; Jin Seok KIM ; Joon Ho MOON ; Chang‑Ki MIN ; Dok Hyun YOON ; Sung‑Soo YOON ; Je‑Jung LEE ; Chae Moon HONG ; Ka‑Won KANG ; Jihyun KWON ; Kyoung Ha KIM ; Dae Sik KIM ; Sung Yong KIM ; Sung‑Hyun KIM ; Yu Ri KIM ; Young Rok DO ; Yeung‑Chul MUN ; Sung‑Soo PARK ; Young Hoon PARK ; Ho Jin SHIN ; Hyeon‑Seok EOM ; Sang Eun YOON ; Sang Mee HWANG ; Won Sik LEE ; Myung‑won LEE ; Jun Ho YI ; Ji Yun LEE ; Ji Hyun LEE ; Ho Sup LEE ; Sung‑Nam LIM ; Jihyang LIM ; Ho‑Young YHIM ; Yoon Hwan CHANG ; Jae‑Cheol JO ; Jinhyun CHO ; Hyungwoo CHO ; Yoon Seok CHOI ; Hee jeong CHO ; Ari AHN ; Jong Han CHOI ; Hyun Jung KIM ; Kihyun KIM
Blood Research 2025;60():9-
Multiple myeloma (MM), a hematological malignancy, is characterized by malignant plasma cell proliferation in the bone marrow. Recent treatment advances have significantly improved patient outcomes associated with MM.In this study, we aimed to develop comprehensive, evidence-based guidelines for the diagnosis, prognosis, and treat‑ ment of MM. We identified 12 key clinical questions essential for MM management, guiding the extensive literature review and meta-analysis of the study. Our guidelines provide evidence-based recommendations by integrating patient preferences with survey data. These recommendations include current and emerging diagnostic tools, thera‑ peutic agents, and treatment strategies. By prioritizing a patient-centered approach and rigorous data analysis, these guidelines were developed to enhance MM management, both in Korea and globally.
3.Presenteeism in Agricultural, Forestry and Fishing Workers:Based on the 6th Korean Working Conditions Survey
Sang-Hee HONG ; Eun-Chul JANG ; Soon-Chan KWON ; Hwa-Young LEE ; Myoung-Je SONG ; Jong-Sun KIM ; Mid-Eum MOON ; Sang-Hyeon KIM ; Ji-Suk YUN ; Young-Sun MIN
Journal of Agricultural Medicine & Community Health 2024;49(1):1-12
Objectives:
Presenteeism is known to be a much more economically damaging social cost than disease rest while going to work despite physical pain. Since COVID-19, social discussions on the sickness benefit have been taking place as a countermeasure against presenteeism, and in particular, farmers and fishermen do not have an institutional mechanism for livelihood support when a disease other than work occurs. This study attempted to examine the relationship between agricultural, fishing, and forestry workers and presenteeism using the 6th Korean Work Conditions Survey.
Methods:
From October 2020 to January 2021, data from the 6th working conditions survey conducted on 17 cities and provinces in Korea were used, and a total of 34,981 people were studied. Control variables were gender, age, self-health assessment, education level, night work, shift work, monthly income, occupation, working hours per week, and employment status.
Results:
As a result of the analysis, farmers and fishermen showed the characteristics of the self-employed and the elderly, and as a result of the regression analysis, when farmers and fishermen analyzed the relationship with presenteeism tendency compared to other industry workers, farmers and fishermen increased by 23% compared to other industry groups.
Conclusion
This study is significant in that it has representation by utilizing the 6th working conditions survey and objectively suggests the need for a sickness benefit for farmers and fishermen who may be overlooked in the sickness benefit.
4.Presenteeism in Agricultural, Forestry and Fishing Workers:Based on the 6th Korean Working Conditions Survey
Sang-Hee HONG ; Eun-Chul JANG ; Soon-Chan KWON ; Hwa-Young LEE ; Myoung-Je SONG ; Jong-Sun KIM ; Mid-Eum MOON ; Sang-Hyeon KIM ; Ji-Suk YUN ; Young-Sun MIN
Journal of Agricultural Medicine & Community Health 2024;49(1):1-12
Objectives:
Presenteeism is known to be a much more economically damaging social cost than disease rest while going to work despite physical pain. Since COVID-19, social discussions on the sickness benefit have been taking place as a countermeasure against presenteeism, and in particular, farmers and fishermen do not have an institutional mechanism for livelihood support when a disease other than work occurs. This study attempted to examine the relationship between agricultural, fishing, and forestry workers and presenteeism using the 6th Korean Work Conditions Survey.
Methods:
From October 2020 to January 2021, data from the 6th working conditions survey conducted on 17 cities and provinces in Korea were used, and a total of 34,981 people were studied. Control variables were gender, age, self-health assessment, education level, night work, shift work, monthly income, occupation, working hours per week, and employment status.
Results:
As a result of the analysis, farmers and fishermen showed the characteristics of the self-employed and the elderly, and as a result of the regression analysis, when farmers and fishermen analyzed the relationship with presenteeism tendency compared to other industry workers, farmers and fishermen increased by 23% compared to other industry groups.
Conclusion
This study is significant in that it has representation by utilizing the 6th working conditions survey and objectively suggests the need for a sickness benefit for farmers and fishermen who may be overlooked in the sickness benefit.
5.Presenteeism in Agricultural, Forestry and Fishing Workers:Based on the 6th Korean Working Conditions Survey
Sang-Hee HONG ; Eun-Chul JANG ; Soon-Chan KWON ; Hwa-Young LEE ; Myoung-Je SONG ; Jong-Sun KIM ; Mid-Eum MOON ; Sang-Hyeon KIM ; Ji-Suk YUN ; Young-Sun MIN
Journal of Agricultural Medicine & Community Health 2024;49(1):1-12
Objectives:
Presenteeism is known to be a much more economically damaging social cost than disease rest while going to work despite physical pain. Since COVID-19, social discussions on the sickness benefit have been taking place as a countermeasure against presenteeism, and in particular, farmers and fishermen do not have an institutional mechanism for livelihood support when a disease other than work occurs. This study attempted to examine the relationship between agricultural, fishing, and forestry workers and presenteeism using the 6th Korean Work Conditions Survey.
Methods:
From October 2020 to January 2021, data from the 6th working conditions survey conducted on 17 cities and provinces in Korea were used, and a total of 34,981 people were studied. Control variables were gender, age, self-health assessment, education level, night work, shift work, monthly income, occupation, working hours per week, and employment status.
Results:
As a result of the analysis, farmers and fishermen showed the characteristics of the self-employed and the elderly, and as a result of the regression analysis, when farmers and fishermen analyzed the relationship with presenteeism tendency compared to other industry workers, farmers and fishermen increased by 23% compared to other industry groups.
Conclusion
This study is significant in that it has representation by utilizing the 6th working conditions survey and objectively suggests the need for a sickness benefit for farmers and fishermen who may be overlooked in the sickness benefit.
6.Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study
Dong Won BAEK ; Han-Seung PARK ; Sang Kyun SOHN ; Dae Young KIM ; Inho KIM ; Jae-Sook AHN ; Young Rok DO ; Se Ryeon LEE ; Hyeon-Seok EOM ; Won-Sik LEE ; Sung-Hyun KIM ; Ho Sup LEE ; Yoo Jin LEE ; Joon Ho MOON ; Je-Hwan LEE ;
The Korean Journal of Internal Medicine 2023;38(5):734-746
Background/Aims:
We performed a prospective study to determine the efficacy and safety of rituximab including chemotherapy in CD20-positive acute lymphoblastic leukemia (ALL).
Methods:
Patients with newly diagnosed ALL, aged ≥ 15 years, were eligible for the study if their leukemic blast cells in bone marrow expressed CD20 ≥ 20% at the time of diagnosis. Patients received multiagent chemotherapy with rituximab. After achieving complete remission (CR), patients received five cycles of consolidation with concomitant rituximab. Rituximab was administered monthly from day 90 of transplantation for patients who received allogeneic hematopoietic cell transplantation.
Results:
In patients with Philadelphia (Ph)-negative ALL, 39 of 41 achieved CR (95.1%), the 2- and 4-year relapse-free survival (RFS) rates were 50.4% and 35.7%, and the 2- and 4-year overall survival (OS) rates were 51.5% and 43.2%, respectively. In the group with Ph-positive ALL, all 32 patients achieved CR, the 2- and 4-year RFS rates were 60.7% and 52.1%, and the 2- and 4-year OS rates were 73.3% and 52.3%, respectively. In the Ph-negative ALL group, patients with higher CD20 positivity experienced more favorable RFS (p < 0.001) and OS (p = 0.06) than those with lower CD20 positivity. Patients who received ≥ 2 cycles of rituximab after transplantation had significantly improved RFS (hazard ratio [HR], 0.31; p = 0.049) and OS (HR, 0.29; p = 0.021) compared with those who received < 2 cycles.
Conclusions
The addition of rituximab to conventional chemotherapy for CD20-positive ALL is effective and tolerable (Clinicaltrials. gov NCT01429610).
7.Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function
Sungim CHOI ; Heun CHOI ; Seong Yeon PARK ; Yee Gyung KWAK ; Je Eun SONG ; So Youn SHIN ; Ji Hyeon BAEK ; Hyun-IL SHIN ; Hong Sang OH ; Yong Chan KIM ; Joon-Sup YEOM ; Jin-Hee HAN ; Min Jae KIM
The Korean Journal of Parasitology 2022;60(1):39-43
Plasmodium vivax exhibits dormant liver-stage parasites, called hypnozoites, which can cause relapse of malaria. The only drug currently used for eliminating hypnozoites is primaquine. The antimalarial properties of primaquine are dependent on the production of oxidized metabolites by the cytochrome P450 isoenzyme 2D6 (CYP2D6). Reduced primaquine metabolism may be related to P. vivax relapses. We describe a case of 4 episodes of recurrence of vivax malaria in a patient with decreased CYP2D6 function. The patient was 52-year-old male with body weight of 52 kg. He received total gastrectomy and splenectomy 7 months before the first episode and was under chemotherapy for the gastric cancer. The first episode occurred in March 2019 and each episode had intervals of 34, 41, and 97 days, respectively. At the first and second episodes, primaquine was administered as 15 mg for 14 days. The primaquine dose was increased with 30 mg for 14 days at the third and fourth episodes. Seven gene sequences of P. vivax were analyzed and revealed totally identical for all the 4 samples. The CYP2D6 genotype was analyzed and intermediate metabolizer phenotype with decreased function was identified.
8.Early diagnosis of Gaucher disease in Korean patients with unexplained splenomegaly: a multicenter observational study
Young Rok DO ; Yunsuk CHOI ; Mi Hwa HEO ; Jin Seok KIM ; Jae-ho YOON ; Je-Hwan LEE ; Joon Seong PARK ; Sang Kyun SOHN ; Sung Hyun KIM ; Sungnam LIM ; Joo Seop CHUNG ; Deog-Yeon JO ; Hyeon Seok EOM ; Hawk KIM ; So Yeon JEON ; Jong-Ho WON ; Hee Jeong LEE ; Jung Won SHIN ; Jun-Ho JANG ; Sung-Soo YOON
Blood Research 2022;57(3):207-215
Background:
Gaucher disease (GD) is an autosomal recessive disorder characterized by excessive accumulation of glucosylceramide in multiple organs. This study was performed to determine the detection rate of GD in a selected patient population with unexplained splenomegaly in Korea.
Methods:
This was a multicenter, observational study conducted at 18 sites in Korea between December 2016 and February 2020. Adult patients with unexplained splenomegaly were enrolled and tested for β-glucosidase enzyme activity on dried blood spots (DBS) and in peripheral blood leukocytes. Mutation analysis was performed if the test was positive or indeterminate for the enzyme assay. The primary endpoint was the percentage of patients with GD in patients with unexplained splenomegaly.
Results:
A total of 352 patients were enrolled in this study (male patients, 199; mean age, 48.42 yr). Amongst them, 14.77% of patients had concomitant hepatomegaly. The most common sign related to GD was splenomegaly (100%), followed by thrombocytopenia (44.32%) and, anemia (40.91%). The β-glucosidase activity assay on DBS and peripheral leukocytes showed abnormal results in sixteen and six patients, respectively. Eight patients were tested for the mutation, seven of whom were negative and one patient showed a positive mutation analysis result. One female patient who presented with splenomegaly and thrombocytopenia was diagnosed with type 1 GD. The detection rate of GD was 0.2841% (exact 95% CI, 0.0072‒).
Conclusion
The detection rate of GD in probable high-risk patients in Korea was lower than expected.However, the role of hemato-oncologists is still important in the diagnosis of GD.
9.A 4-Week, Two-Center, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of EOPatch in Well-Controlled Type 1 Diabetes Mellitus
Jiyun PARK ; Nammi PARK ; Sangjin HAN ; You-Bin LEE ; Gyuri KIM ; Sang-Man JIN ; Woo Je LEE ; Jae Hyeon KIM
Diabetes & Metabolism Journal 2022;46(6):941-947
This study evaluated the safety and efficacy of tubeless patch pump called EOPatch in patients with well-controlled type 1 diabetes mellitus (T1DM). This 4-week, two-center, open-label, single-arm study enrolled 10 adult patients diagnosed with T1DM with glycosylated hemoglobin less than 7.5%. The co-primary end points were patch pump usage time for one attachment and number of serious adverse events related to the patch pump. The secondary end points were total amount of insulin injected per patch and changes in glycemic parameters including continuous glucose monitoring data compared to those at study entry. The median usage time per patch was 84.00 hours (interquartile range, 64.50 to 92.50). Serious adverse events did not occur during the trial. Four weeks later, time in range 70 to 180 mg/dL was significantly improved (70.71%±17.14 % vs. 82.96%±9.14%, P=0.01). The times spent below range (<54 mg/dL) and above range (>180 mg/dL) also improved (All P<0.05). Four-week treatment with a tubeless patch pump was safe and led to clinical improvement in glycemic control.
10.Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19:Real-World Data during the Delta Variant Predominance
Yee Gyung KWAK ; Je Eun SONG ; Jieun KANG ; Jiyeon KANG ; Hyung Koo KANG ; Hyeon-Kyoung KOO ; Hye Kyeong PARK ; Sang Bong CHOI ; Hyuk Pyo LEE ; Myung Jin LEE ; Baek-Nam KIM
Infection and Chemotherapy 2022;54(4):781-786
Regdanvimab is the only monoclonal antibody available in Korea that targets severe acute respiratory syndrome coronavirus 2. We retrospectively evaluated the clinical characteristics of 374 adults hospitalized with coronavirus disease 2019 (COVID-19) who were treated with regdanvimab from September through December 2021. In total, 322 (86.1%) patients exhibited risk factors for disease progression. Most patients (91.4%) improved without additional treatment. No patient died or was transferred to intensive care. This study shows that regdanvimab prevented disease progression in high-risk patients with mild to moderate COVID-19 infections during Delta variant predominance.

Result Analysis
Print
Save
E-mail